Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
HTG Molecular Diagnostics logo — HTG is focused on advancing precision medicine

HTG Molecular Diagnostics

HTG is focused on advancing precision medicine

Founded 1997 United States Tucson, United States 33 employees Post-IPO Equity Total: $106.51M Biotechnology, Health Care +1

General Information

Company Name HTG Molecular Diagnostics
Founded Year 1997
Location United States Tucson, United States
Founders / Decision Makers
Team member Team member Team member
Employees 33
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with HTG Molecular Diagnostics. To contact HTG Molecular Diagnostics, visit htgmolecular.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does HTG Molecular Diagnostics compare?

A PDF of HTG Molecular Diagnostics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting HTG Molecular Diagnostics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About HTG Molecular Diagnostics

HTG Molecular Diagnostics is a biotechnology startup headquartered in the United States. Since its founding in 1997, the company has been dedicated to advancing precision medicine. Their mission, encapsulated in the slogan "HTG is focused on advancing precision medicine," resonates with the growing trend of personalized healthcare. HTG's approach involves harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics, and targeted therapeutics across various disease areas. With a track record spanning over a decade, HTG has established innovative partnerships with biopharma leaders and major academic institutes. This has led to the development of proprietary RNA platform technologies designed to enhance the effectiveness and efficiency of life science tools and diagnostics. HTG also aims to unlock a differentiated and disruptive approach to transformative drug discovery, positioning itself at the forefront of the rapidly evolving biotechnology landscape. In a recent significant development, HTG Molecular Diagnostics raised a $10.00M Post-IPO Equity investment on 21 December 2022. This injection of funds showcases the confidence investors have in HTG's vision and potential. As precision medicine continues to gain traction, HTG's innovative solutions and strategic partnerships bode well for its future growth and impact in the field.

Business keywords: Precision Medicine, Transcriptome Profiling, Clinical Diagnostics, Therapeutics, Biopharma Partnerships, RNA Platform Technologies, Life Science Tools, Diagnostics, NGS-adapted Chemistry, HTG EdgeSeq Technology, Molecular Profiling, Sequencing, Gene Expression, Companion Diagnostics, Molecular-based Technology

Funding Rounds & Investors (14)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $10.00M -
21 Dec 2022
Post IPO Equity $7.50M -
18 Mar 2022
Post IPO Equity $22.50M -
03 Oct 2019
Debt Financing $16.00M 2
Silicon Valley Bank, Oxford Finance LLC
29 Aug 2014
Series E $7.48M -
13 Feb 2014
Venture Round $7.56M -
14 Nov 2012
Series D $16.20M 6
Novo Holdings Solstice Capital SR One
Novo Holdings, Solstice Capital +4
13 Jun 2011
Debt Financing $1.74M -
06 Aug 2010
Series C $4.31M -
23 Jul 2009
Series C $2.80M 3
Solstice Capital Valley Ventures
Solstice Capital, Valley Ventures +1
28 Nov 2008

View All 14 Funding Rounds

HTG Molecular Diagnostics Alternatives & Competitors

View All Alternatives
HTG Molecular Diagnostics vs
DxTerity
DxTerity United States

Bringing the power of precision medicine to autoimmune disease

Venture round
31 employees
Biotechnology, Health Care
Compare HTG Molecular Diagnostics vs DxTerity
HTG Molecular Diagnostics vs
Predicine
Predicine United States

Advancing precision medicine through next-generation liquid biopsy oncology platform

89 employees
Biotechnology, Health Care
Compare HTG Molecular Diagnostics vs Predicine
HTG Molecular Diagnostics vs
Molecular Testing Labs
Molecular Testing Labs United States

Powering Health Diagnostics

168 employees
Biotechnology, Health Care
Also compare with: HTG Molecular Diagnostics vs GeneCast Biotechnology Co., Ltd. GeneCast Biotechnology Co., Ltd. HTG Molecular Diagnostics vs QuantumCyte, Inc. QuantumCyte, Inc. View all alternatives

FAQ About HTG Molecular Diagnostics

HTG is focused on advancing precision medicine
HTG Molecular Diagnostics was founded in 1997.
HTG Molecular Diagnostics is headquartered in Tucson, United States.
HTG Molecular Diagnostics operates in Biotechnology, Health Care and Life Sciences. Its work centres on Precision Medicine, Transcriptome Profiling, Clinical Diagnostics and Therapeutics.
HTG Molecular Diagnostics has approximately 33 employees.
HTG Molecular Diagnostics has completed 14 funding rounds, raising a total of $106.51M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to HTG Molecular Diagnostics include DxTerity, Predicine, Molecular Testing Labs, Invivoscribe, GeneCast Biotechnology Co., Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
HTG Molecular Diagnostics and DxTerity are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for HTG Molecular Diagnostics, https://bouncewatch.com/company/htg-molecular-diagnostics, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout